1yr
.png?VersionId=TaIrZLwNaRGf1X1SIyW3BdPiWe8gYiYb)
Share
1yr
.png?VersionId=rt9oyYoO1YSqCL_g9QVUG1QL9AaAG6Vg)
Share
1yr
Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38678642/
Absolute mass changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B can explain results of the PROMINENT trial. The 3 mg/dL (0.08 mmol/L) higher total atherogenic cholesterol together with 5...
The study suggests that absolute changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B explain the neutral results of the PROMINENT trial, with higher atherogenic cholesterol and apolipoprotein B linked to more ASCVD.
Share
1yr
Higher Cholesterol Absorption Marker at Baseline Predicts Fewer Cardiovascular Events in Elderly Patients Receiving Hypercholesterolemia Treatment: The KEEP Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38240241/
URL: https://www.umin.ac.jp; unique identifier: UMIN000017769.
The KEEP study found that higher baseline campesterol levels in older individuals with hypercholesterolemia were associated with a lower risk of cardiovascular events, regardless of ezetimibe treatment.
Share
1yr
Emerging Myositis Treatments and Targeted Therapies – Insights from IgNS 2024
In this IgNS 2024 conference video, Dr. Eleni Tiniakou, a rheumatologist and assistant professor at Johns Hopkins, shares advancements in myositis treatment approaches. She highlights evidence-based therapies, including interferon pathway inhibitors, B-cell targeting, and early research on CAR T-cell applications. Dr. Tiniakou emphasizes the importance of personalized approaches to address the diverse pathogenic factors in myositis treatment. These insights provide physicians tools to better tailor treatments across myositis subtypes and improve patient outcomes.
Share